ClinicalTrials.gg
CompletedNCT04895982Updated Oct 9, 2024Results posted

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

A Phase 2 interventional study of BNT162b2 in SARS-CoV-2 Infection, COVID19, sponsored by BioNTech SE. Completed at 30 sites in 4 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by BioNTech SE · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
45th of 54
124 · median 575
Started
2021
with 29 others
Phase 2
16 of 54
1 open now
Registered
14th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 45th largest by enrollment, is one of 30 that started in 2021, is one of 16 in phase 2, and was the 14th registered.

COVID-19

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised. Participants are going to be followed up for 6 months after dose 4, and each participant is projected to be on the study for approximately 15 months. This study will be conducted in the United States, Brazil, Germany and Mexico.

03

Conditions studied

  • SARS-CoV-2 Infection, COVID19

Keywords

  • COVID19
  • Coronavirus
  • Vaccine
  • SARS-CoV-2
  • RNA Vaccine
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants who are ≥2 years of age at the time of enrollment (Visit 1).
  2. Participants or participants' parent(s)/legal guardians, as age appropriate, who sign consent, and are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  3. ≥12 months (365 days) in the opinion of the investigator at enrollment (Visit 1).
  4. Participants or participant's parent(s)/legal guardians, as age appropriate, who are able to be contacted by telephone throughout the study period.
  5. Female participant of or male participant able to father children who is willing to use a highly effective method of as outlined in this protocol for at least 28 days after the last dose of study intervention if at risk of pregnancy with her/his partner; or female participant not of childbearing potential or male participant not able to father children.
  6. Participants who are by virtue of the following:

    • Having known non-small cell lung cancer (NSCLC) and is ≥18 years of age with at least 1 of the following:

      • Who received chemotherapy at least 2 weeks (14 days) before enrollment (or is treatment naïve), and is not expected to receive chemotherapy within at least 2 weeks (14 days) after dose administration; and/or
      • Receiving treatment (programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitor, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor) and has undergone at least 1 treatment cycle prior to enrollment (at Visit 1); or
      • Receiving targeted drug therapy treatment (epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene tyrosine-protein kinase (ROS1), v-raf murine sarcoma viral oncogene homolog B1 (BRAF),rearranged during transfection (RET),hepatocyte growth factor receptor (MET), neurotrophic tyrosine kinase (NTRK) inhibitors) and has undergone at least 1 treatment cycle prior to enrollment (at Visit 1); or
    • Having known chronic lymphocytic leukemia (CLL) and is ≥18 years of age with at least 1 of the following:

      • Has asymptomatic disease (eg, Rai stage \<3, Binet stage A or B) and is undergoing observation and does not receive any treatment for CLL; or
      • Receiving B-cell inhibitory monoclonal antibody treatment (anti-CD20) and has received at least 3 cycles prior to enrollment; and/or
      • Receives a Bruton tyrosine kinase (BTK) inhibitor, phosphoinositide 3-kinase (PI3K) inhibitor, or B-cell lymphoma-2 (BCL-2) inhibitor; or
    • Is currently undergoing maintenance hemodialysis treatment secondary to end-stage renal disease and is ≥18 years of age; or
    • Is on active immunomodulator therapy (eg, tumor necrosis factor alpha (TNFα) inhibitor, or tofacitinib or methotrexate) for an or inflammatory disease disorder (eg, inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, and inflammatory bowel disease, such as ulcerative colitis and Crohn's disease) at a stable* dose

      *Stable dose is defined as receiving the same dose for at least 3 months (84 days) with no changes in the 28 days prior to Visit 1; or

    • Receiving a solid organ transplant at least 3 months (84 days) prior to enrollment (Visit 1) and with no acute rejection episodes within 2 months (60 days) prior to enrollment (Visit 1), and is ≥2 to \<18 years of age; or
    • Has had an autologous or allogenic bone marrow or stem cell transplant at least 6 months (182 days) prior to enrollment (Visit 1), with adequate immune reconstitution for immunization, in the investigator's opinion, and is ≥2 to \<18 years of age
  7. The participant or participant's parent(s)/legal guardian is capable of giving signed , and assent (as appropriate), which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. The investigator, or a person designated by the investigator, will obtain written informed consent (and assent, as appropriate) from each study participant or participant's parent(s)/legal guardian before any study-specific activity is performed. All parent(s)/legal guardians should be fully informed, and participants should be informed to the fullest extent possible, about the study in language and terms they are able to understand. The investigator will retain the original copy of each participant's signed consent (and assent, as appropriate) document(s).

Exclusion criteria

Exclusion Criteria:

  1. Past clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19, or a past clinical diagnosis of multisystem inflammatory syndrome in children (MIS-C).
  2. Participants with active graft-vs-host disease (), transplant rejection, or posttransplant lymphoproliferative disorder (PTLD), or participants who have had treatment for these conditions within 3 months (84 days) prior to study enrollment (Visit 1).
  3. Participants \<18 years of age whose weight is less than the 5th percentile of age-adjusted ideal body weight.
  4. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  5. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  6. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  7. Participant who is pregnant or breastfeeding.
  8. Participants who may be ineligible because of the number of phlebotomy assessments during this study, in the opinion of the investigator.
  9. Participants who do not have adequate deltoid muscle mass to allow intramuscular vaccination, in the opinion of the investigator.
  10. Previous vaccination with any coronavirus vaccine.
  11. Ongoing, or history of, treatment with blood/plasma products or immunoglobulins within 3 months (84 days) prior to Dose 1 or planned receipt of these medications prior to Dose 4.
  12. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
  13. Previous participation in other studies involving study intervention containing lipid nanoparticle (LNPs).
  14. Participants who are direct descendants (child or grandchild) of site staff members or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  15. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    BNT162b2

    Intramuscular Injection

    Biological: BNT162b2

Interventions

  • BiologicalBNT162b2

    Intramuscular Injection

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

    GMTs and corresponding 2-sided confidence intervals (CIs) were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 Evaluable Immunogenicity population (EIP).

    Time frame: 1 Month after Vaccination 3

  2. GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

    GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.

    Time frame: 1 Month after Vaccination 3

  3. GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

    GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.

    Time frame: 1 Month after Vaccination 3

  4. GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

    GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.

    Time frame: 1 Month after Vaccination 3

  5. GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

    GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.

    Time frame: 1 Month after Vaccination 4

  6. GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

    GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.

    Time frame: 1 Month after Vaccination 4

  7. GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

    GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.

    Time frame: 1 Month after Vaccination 4

  8. GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

    GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP .

    Time frame: 1 Month after Vaccination 4

  9. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=2 to <5 Years

    Local reactions were collected in an electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\>0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 1

  10. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=5 to <12 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 1

  11. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=12 to <18 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 1

  12. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=18 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 1

  13. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=2 to <5 Years

    Local reactions collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate(\>2.0 to 7.0 cm), severe(\>7.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis\[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate(interfered with activity), severe(prevented daily activity),Grade 4(ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 2

  14. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=5 to <12 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 2

  15. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=12 to <18 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 2

  16. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=18 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 2

  17. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=2 to <5 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 3

  18. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=5 to <12 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 3

  19. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=12 to <18 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate(\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate(interfered with activity), severe(prevented daily activity) and Grade 4(ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 3

  20. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=18 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 3

  21. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=2 to <5 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 4

  22. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=5 to <12 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 4

  23. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=12 to <18 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 4

  24. Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=18 Years

    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 4

  25. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=2 to <5 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 degree C (deg C); categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 1

  26. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=5 to <12 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 1

  27. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=12 to <18 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 1

  28. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=18 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 1

  29. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=2 to <5 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 2

  30. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=5 to <12 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 2

  31. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=12 to <18 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 2

  32. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=18 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 2

  33. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=2 to <5 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 3

  34. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=5 to <12 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 3

  35. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=12 to <18 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 3

  36. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=18 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 3

  37. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=2 to <5 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 4

  38. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=5 to <12 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 de, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 4

  39. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=12 to <18 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 4

  40. Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=18 Years

    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after Vaccination 4

  41. Percentage of Participants Reporting at Least 1 Adverse Event (AE) After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=2 to <5 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 1 to 1 month after Vaccination 2

  42. Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=5 to <12 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 1 to 1 month after Vaccination 2

  43. Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=12 to <18 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 1 to 1 month after Vaccination 2

  44. Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=18 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 1 to 1 month after Vaccination 2

  45. Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 3 to 1 month after Vaccination 3

  46. Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 3 to 1 month after Vaccination 3

  47. Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=12 to <18 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 3 to 1 month after Vaccination 3

  48. Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=18 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 3 to 1 month after Vaccination 3

  49. Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 4 to 1 month after Vaccination 4

  50. Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 4 to 1 month after Vaccination 4

  51. Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=12 to <18 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 4 to 1 month after Vaccination 4

  52. Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=18 Years

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 4 to 1 month after Vaccination 4

  53. Percentage of Participants Reporting Serious Adverse Events (SAEs) From Vaccination 1 Through the Duration of the Study in Participants Aged >=2 to <5 Years

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)

  54. Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=5 to <12 Years

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)

  55. Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=12 to <18 Years

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)

  56. Percentage of Participants Reporting SAEs From Dose 1 Through the Duration of the Study in Participants Aged >=18 Years

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)

07

Results

Posted Oct 9, 2024

Participant flow

Participant flow — Overall Study
Milestone(Greater Than or Equal to (>=) 2 to Less Than (<) 5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Started91513192422717511
Dose 191513192422717511
Dose 291512192422717511
Dose 391511172422716511
Dose 47136142017513310
Completed7126162018503310
Not completed237344214201
Withdrew: Withdrawal by subject000001100101
Withdrew: Withdrawal by parent/guardian233132103000
Withdrew: Other001100000100
Withdrew: Protocol violation001110010000
Withdrew: Lost to follow-up001001001000
Withdrew: Refused further study procedures001000000000

Outcome measures

PrimaryGeometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

GMTs and corresponding 2-sided confidence intervals (CIs) were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 Evaluable Immunogenicity population (EIP).

Time frame:
1 Month after Vaccination 3
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
Titers>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection600.2 (77.8 to 4629.8)884.7 (176.7 to 4430.6)—
PrimaryGMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.

Time frame:
1 Month after Vaccination 3
Reported as:
Geometric mean · Titers
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
Titers>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection758.4 (123.7 to 4650.4)741.2 (150.6 to 3647.0)4592.3 (1989.5 to 10600.4)
PrimaryGMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.

Time frame:
1 Month after Vaccination 3
Reported as:
Geometric mean · Titers
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
Titers>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection7330.0 (NA to NA)43.5 (NA to NA)2368.1 (1679.9 to 3338.3)
PrimaryGMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.

Time frame:
1 Month after Vaccination 3
Reported as:
Geometric mean · Titers
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
Titers>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection596.5 (0.1 to 3699753.4)—115.0 (NA to NA)
PrimaryGMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.

Time frame:
1 Month after Vaccination 4
Reported as:
Geometric mean · Titers
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
Titers>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection837.5 (1.4 to 518774.5)9576.3 (0.0 to 2070132632.7)—
PrimaryGMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.

Time frame:
1 Month after Vaccination 4
Reported as:
Geometric mean · Titers
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
Titers>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection754.2 (0.0 to 351878145.2)5335.3 (517.0 to 55061.8)5330.8 (0.0 to 113927797661576)
PrimaryGMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.

Time frame:
1 Month after Vaccination 4
Reported as:
Geometric mean · Titers
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
Titers>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection—2845.0 (NA to NA)—
PrimaryGMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection

GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP .

Time frame:
1 Month after Vaccination 4
Reported as:
Geometric mean · Titers
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
Titers>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection1474.0 (NA to NA)——
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=2 to <5 Years

Local reactions were collected in an electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\>0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Redness: Any11.1 ± 0.36.7 ± 0.20 ± 0.0
Redness: Mild11.1 ± 0.36.7 ± 0.20 ± 0.0
Redness: Moderate0 ± 0.00 ± 0.00 ± 0.0
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any0 ± 0.00 ± 0.00 ± 0.0
Swelling: Mild0 ± 0.00 ± 0.00 ± 0.0
Swelling: Moderate0 ± 0.00 ± 0.00 ± 0.0
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at the injection site: Any11.1 ± 0.313.3 ± 1.723.1 ± 5.0
Pain at the injection site: Mild11.1 ± 0.313.3 ± 1.723.1 ± 5.0
Pain at the injection site: Moderate0 ± 0.00 ± 0.00 ± 0.0
Pain at the injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at the injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=5 to <12 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Redness: Any10.5 ± 1.38.3 ± 1.09.1 ± 1.1
Redness: Mild10.5 ± 1.34.2 ± 0.14.5 ± 0.1
Redness: Moderate0 ± 0.04.2 ± 0.14.5 ± 0.1
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any5.3 ± 0.14.2 ± 0.118.2 ± 5.2
Swelling: Mild5.3 ± 0.10 ± 0.013.6 ± 2.9
Swelling: Moderate0 ± 0.04.2 ± 0.14.5 ± 0.1
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at the injection site: Any73.7 ± 48.858.3 ± 36.654.5 ± 32.2
Pain at the injection site: Mild52.6 ± 28.950.0 ± 29.145.5 ± 24.4
Pain at the injection site: Moderate21.1 ± 6.18.3 ± 1.09.1 ± 1.1
Pain at the injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at the injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=12 to <18 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Redness: Any28.6 ± 3.70 ± 0.014.3 ± 0.4
Redness: Mild28.6 ± 3.70 ± 0.014.3 ± 0.4
Redness: Moderate0 ± 0.00 ± 0.00 ± 0.0
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any28.6 ± 3.7100.0 ± 2.514.3 ± 0.4
Swelling: Mild0 ± 0.0100.0 ± 2.50 ± 0.0
Swelling: Moderate28.6 ± 3.70 ± 0.014.3 ± 0.4
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at the injection site: Any85.7 ± 42.1100.0 ± 2.557.1 ± 18.4
Pain at the injection site: Mild71.4 ± 29.0100.0 ± 2.528.6 ± 3.7
Pain at the injection site: Moderate14.3 ± 0.40 ± 0.028.6 ± 3.7
Pain at the injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at the injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=18 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Redness: Any0 ± 0.00 ± 0.00 ± 0.0
Redness: Mild0 ± 0.00 ± 0.00 ± 0.0
Redness: Moderate0 ± 0.00 ± 0.00 ± 0.0
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any0 ± 0.00 ± 0.00 ± 0.0
Swelling: Mild0 ± 0.00 ± 0.00 ± 0.0
Swelling: Moderate0 ± 0.00 ± 0.00 ± 0.0
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Any80.0 ± 28.4100.0 ± 2.5100.0 ± 2.5
Pain at injection site: Mild40.0 ± 5.3100.0 ± 2.50 ± 0.0
Pain at injection site: Moderate40.0 ± 5.30 ± 0.0100.0 ± 2.5
Pain at injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=2 to <5 Years

Local reactions collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate(\>2.0 to 7.0 cm), severe(\>7.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis\[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate(interfered with activity), severe(prevented daily activity),Grade 4(ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Redness: Any0 (0.0 to 33.6)6.7 (0.2 to 31.9)0 (0.0 to 30.8)
Redness: Mild0 (0.0 to 33.6)6.7 (0.2 to 31.9)0 (0.0 to 30.8)
Redness: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Redness: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Redness: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Swelling: Any0 (0.0 to 33.6)6.7 (0.2 to 31.9)0 (0.0 to 30.8)
Swelling: Mild0 (0.0 to 33.6)6.7 (0.2 to 31.9)0 (0.0 to 30.8)
Swelling: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Swelling: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Swelling: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Pain at injection site: Any11.1 (0.3 to 48.2)20.0 (4.3 to 48.1)9.1 (0.2 to 41.3)
Pain at injection site: Mild11.1 (0.3 to 48.2)20.0 (4.3 to 48.1)9.1 (0.2 to 41.3)
Pain at injection site: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 28.5)
Pain at injection site: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 28.5)
Pain at injection site: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 28.5)
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=5 to <12 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Redness: Any10.5 ± 1.312.5 ± 2.722.7 ± 7.8
Redness: Mild10.5 ± 1.34.2 ± 0.113.6 ± 2.9
Redness: Moderate0 ± 0.08.3 ± 1.09.1 ± 1.1
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any10.5 ± 1.38.3 ± 1.031.8 ± 13.9
Swelling: Mild10.5 ± 1.34.2 ± 0.19.1 ± 1.1
Swelling: Moderate0 ± 0.04.2 ± 0.122.7 ± 7.8
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Any68.4 ± 43.462.5 ± 40.650.0 ± 28.2
Pain at injection site: Mild52.6 ± 28.945.8 ± 25.622.7 ± 7.8
Pain at injection site: Moderate15.8 ± 3.416.7 ± 4.727.3 ± 10.7
Pain at injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=12 to <18 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Redness: Any14.3 (0.4 to 57.9)0 (0.0 to 97.5)16.7 (0.4 to 64.1)
Redness: Mild14.3 (0.4 to 57.9)0 (0.0 to 97.5)16.7 (0.4 to 64.1)
Redness: Moderate0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Redness: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Redness: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Swelling: Any28.6 (3.7 to 71.0)0 (0.0 to 97.5)16.7 (0.4 to 64.1)
Swelling: Mild0 (0.0 to 41.0)0 (0.0 to 97.5)16.7 (0.4 to 64.1)
Swelling: Moderate28.6 (3.7 to 71.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Swelling: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Swelling: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Pain at injection site: Any85.7 (42.1 to 99.6)100.0 (2.5 to 100.0)57.1 (18.4 to 90.1)
Pain at injection site: Mild57.1 (18.4 to 90.1)100.0 (2.5 to 100.0)28.6 (3.7 to 71.0)
Pain at injection site: Moderate28.6 (3.7 to 71.0)0 (0.0 to 97.5)28.6 (3.7 to 71.0)
Pain at injection site: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 41.0)
Pain at injection site: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 41.0)
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=18 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Redness: Any0 ± 0.00 ± 0.00 ± 0.0
Redness: Mild0 ± 0.00 ± 0.00 ± 0.0
Redness: Moderate0 ± 0.00 ± 0.00 ± 0.0
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any0 ± 0.00 ± 0.00 ± 0.0
Swelling: Mild0 ± 0.00 ± 0.00 ± 0.0
Swelling: Moderate0 ± 0.00 ± 0.00 ± 0.0
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Any80.0 ± 28.4100.0 ± 2.50 ± 0.0
Pain at injection site: Mild60.0 ± 14.7100.0 ± 2.50 ± 0.0
Pain at injection site: Moderate20.0 ± 0.50 ± 0.00 ± 0.0
Pain at injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=2 to <5 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Redness: Any11.1 ± 0.313.3 ± 1.70 ± 0.0
Redness: Mild0 ± 0.06.7 ± 0.20 ± 0.0
Redness: Moderate11.1 ± 0.36.7 ± 0.20 ± 0.0
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any11.1 ± 0.36.7 ± 0.20 ± 0.0
Swelling: Mild0 ± 0.00 ± 0.00 ± 0.0
Swelling: Moderate11.1 ± 0.36.7 ± 0.20 ± 0.0
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Any22.2 ± 2.813.3 ± 1.79.1 ± 0.2
Pain at injection site: Mild0 ± 0.013.3 ± 1.79.1 ± 0.2
Pain at injection site: Moderate22.2 ± 2.80 ± 0.00 ± 0.0
Pain at injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=5 to <12 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Redness: Any29.4 ± 10.34.3 ± 0.114.3 ± 3.0
Redness: Mild17.6 ± 3.80 ± 0.09.5 ± 1.2
Redness: Moderate11.8 ± 1.54.3 ± 0.14.8 ± 0.1
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any17.6 ± 3.88.7 ± 1.114.3 ± 3.0
Swelling: Mild5.9 ± 0.10 ± 0.09.5 ± 1.2
Swelling: Moderate11.8 ± 1.58.7 ± 1.14.8 ± 0.1
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Any70.6 ± 44.026.1 ± 10.257.1 ± 34.0
Pain at injection site: Mild35.3 ± 14.221.7 ± 7.542.9 ± 21.8
Pain at injection site: Moderate35.3 ± 14.24.3 ± 0.114.3 ± 3.0
Pain at injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=12 to <18 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate(\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate(interfered with activity), severe(prevented daily activity) and Grade 4(ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Redness: Any14.3 (0.4 to 57.9)0 (0.0 to 97.5)0 (0.0 to 45.9)
Redness: Mild0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Redness: Moderate14.3 (0.4 to 57.9)0 (0.0 to 97.5)0 (0.0 to 45.9)
Redness: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Redness: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Swelling: Any28.6 (3.7 to 71.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Swelling: Mild0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Swelling: Moderate28.6 (3.7 to 71.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Swelling: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Swelling: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Pain at injection site: Any71.4 (29.0 to 96.3)100.0 (2.5 to 100.0)66.7 (22.3 to 95.7)
Pain at injection site: Mild28.6 (3.7 to 71.0)100.0 (2.5 to 100.0)33.3 (4.3 to 77.7)
Pain at injection site: Moderate42.9 (9.9 to 81.6)0 (0.0 to 97.5)33.3 (4.3 to 77.7)
Pain at injection site: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Pain at injection site: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=18 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Redness: Any25.0 ± 0.6—0 ± 0.0
Redness: Mild25.0 ± 0.6—0 ± 0.0
Redness: Moderate0 ± 0.0—0 ± 0.0
Redness: Severe0 ± 0.0—0 ± 0.0
Redness: Grade 40 ± 0.0—0 ± 0.0
Swelling: Any25.0 ± 0.6—0 ± 0.0
Swelling: Mild25.0 ± 0.6—0 ± 0.0
Swelling: Moderate0 ± 0.0—0 ± 0.0
Swelling: Severe0 ± 0.0—0 ± 0.0
Swelling: Grade 40 ± 0.0—0 ± 0.0
Pain at injection site: Any75.0 ± 19.4—0 ± 0.0
Pain at injection site: Mild50.0 ± 6.8—0 ± 0.0
Pain at injection site: Moderate25.0 ± 0.6—0 ± 0.0
Pain at injection site: Severe0 ± 0.0—0 ± 0.0
Pain at injection site: Grade 40 ± 0.0—0 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=2 to <5 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Redness: Any28.6 ± 3.716.7 ± 0.40 ± 0.0
Redness: Mild14.3 ± 0.40 ± 0.00 ± 0.0
Redness: Moderate14.3 ± 0.416.7 ± 0.40 ± 0.0
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any14.3 ± 0.40 ± 0.016.7 ± 0.4
Swelling: Mild0 ± 0.00 ± 0.016.7 ± 0.4
Swelling: Moderate14.3 ± 0.40 ± 0.00 ± 0.0
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Any28.6 ± 3.70 ± 0.016.7 ± 0.4
Pain at injection site: Mild28.6 ± 3.70 ± 0.016.7 ± 0.4
Pain at injection site: Moderate0 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=5 to <12 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Redness: Any8.3 ± 0.25.3 ± 0.120.0 ± 4.3
Redness: Mild8.3 ± 0.25.3 ± 0.16.7 ± 0.2
Redness: Moderate0 ± 0.00 ± 0.013.3 ± 1.7
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Redness: Grade 40 ± 0.00 ± 0.00 ± 0.0
Swelling: Any16.7 ± 2.15.3 ± 0.120.0 ± 4.3
Swelling: Mild8.3 ± 0.25.3 ± 0.113.3 ± 1.7
Swelling: Moderate8.3 ± 0.20 ± 0.06.7 ± 0.2
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Grade 40 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Any91.7 ± 61.542.1 ± 20.340.0 ± 16.3
Pain at injection site: Mild41.7 ± 15.231.6 ± 12.626.7 ± 7.8
Pain at injection site: Moderate50.0 ± 21.110.5 ± 1.313.3 ± 1.7
Pain at injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at injection site: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=12 to <18 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Redness: Any75.0 (19.4 to 99.4)0 (0.0 to 97.5)66.7 (9.4 to 99.2)
Redness: Mild75.0 (19.4 to 99.4)0 (0.0 to 97.5)66.7 (9.4 to 99.2)
Redness: Moderate0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Redness: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Redness: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Swelling: Any50.0 (6.8 to 93.2)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Swelling: Mild0 (0.0 to 60.2)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Swelling: Moderate50.0 (6.8 to 93.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Swelling: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Swelling: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Pain at injection site: Any75.0 (19.4 to 99.4)100.0 (2.5 to 100.0)33.3 (0.8 to 90.6)
Pain at injection site: Mild25.0 (0.6 to 80.6)100.0 (2.5 to 100.0)0 (0.0 to 70.8)
Pain at injection site: Moderate50.0 (6.8 to 93.2)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Pain at injection site: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Pain at injection site: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
PrimaryPercentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=18 Years

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Redness: Any33.3 ± 0.80 ± 0.0—
Redness: Mild33.3 ± 0.80 ± 0.0—
Redness: Moderate0 ± 0.00 ± 0.0—
Redness: Severe0 ± 0.00 ± 0.0—
Redness: Grade 40 ± 0.00 ± 0.0—
Swelling: Any33.3 ± 0.80 ± 0.0—
Swelling: Mild33.3 ± 0.80 ± 0.0—
Swelling: Moderate0 ± 0.00 ± 0.0—
Swelling: Severe0 ± 0.00 ± 0.0—
Swelling: Grade 40 ± 0.00 ± 0.0—
Pain at injection site: Any66.7 ± 9.4100.0 ± 2.5—
Pain at injection site: Mild33.3 ± 0.8100.0 ± 2.5—
Pain at injection site: Moderate33.3 ± 0.80 ± 0.0—
Pain at injection site: Severe0 ± 0.00 ± 0.0—
Pain at injection site: Grade 40 ± 0.00 ± 0.0—
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=2 to <5 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 degree C (deg C); categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Fever: Any0 ± 0.00 ± 0.015.4 ± 1.9
Fever: >=38.0 to 38.4 deg C0 ± 0.00 ± 0.07.7 ± 0.2
Fever: >38.4 to 38.9 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.9 to 40.0 deg C0 ± 0.00 ± 0.07.7 ± 0.2
Fever: >40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Any22.2 ± 2.86.7 ± 0.27.7 ± 0.2
Fatigue: Mild11.1 ± 0.30 ± 0.00 ± 0.0
Fatigue: Moderate11.1 ± 0.36.7 ± 0.27.7 ± 0.2
Fatigue: Severe0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Grade 40 ± 0.00 ± 0.00 ± 0.0
Headache: Any0 ± 0.00 ± 0.00 ± 0.0
Headache: Mild0 ± 0.00 ± 0.00 ± 0.0
Headache: Moderate0 ± 0.00 ± 0.00 ± 0.0
Headache: Severe0 ± 0.00 ± 0.00 ± 0.0
Headache: Grade 40 ± 0.00 ± 0.00 ± 0.0
Chills: Any11.1 ± 0.30 ± 0.07.7 ± 0.2
Chills: Mild11.1 ± 0.30 ± 0.00 ± 0.0
Chills: Moderate0 ± 0.00 ± 0.07.7 ± 0.2
Chills: Severe0 ± 0.00 ± 0.00 ± 0.0
Chills: Grade 40 ± 0.00 ± 0.00 ± 0.0
Vomiting: Any11.1 ± 0.30 ± 0.023.1 ± 5.0
Vomiting: Mild11.1 ± 0.30 ± 0.07.7 ± 0.2
Vomiting: Moderate0 ± 0.00 ± 0.015.4 ± 1.9
Vomiting: Severe0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Grade 40 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Any0 ± 0.020.0 ± 4.37.7 ± 0.2
Diarrhea: Mild0 ± 0.020.0 ± 4.30 ± 0.0
Diarrhea: Moderate0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Severe0 ± 0.00 ± 0.07.7 ± 0.2
Diarrhea: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Any11.1 ± 0.30 ± 0.00 ± 0.0
New or worsened muscle pain: Mild0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Moderate11.1 ± 0.30 ± 0.00 ± 0.0
New or worsened muscle pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Any11.1 ± 0.30 ± 0.00 ± 0.0
New or worsened joint pain: Mild0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Moderate11.1 ± 0.30 ± 0.00 ± 0.0
New or worsened joint pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=5 to <12 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Fever: Any0 (0.0 to 17.6)4.2 (0.1 to 21.1)0 (0.0 to 15.4)
Fever: >=38.0 to 38.4 deg C0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Fever: >38.4 to 38.9 deg C0 (0.0 to 17.6)4.2 (0.1 to 21.1)0 (0.0 to 15.4)
Fever: >38.9 to 40.0 deg C0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Fever: >40.0 deg C0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Fatigue: Any47.4 (24.4 to 71.1)37.5 (18.8 to 59.4)22.7 (7.8 to 45.4)
Fatigue: Mild31.6 (12.6 to 56.6)20.8 (7.1 to 42.2)13.6 (2.9 to 34.9)
Fatigue: Moderate15.8 (3.4 to 39.6)16.7 (4.7 to 37.4)9.1 (1.1 to 29.2)
Fatigue: Severe0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Fatigue: Grade 40 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Headache: Any42.1 (20.3 to 66.5)12.5 (2.7 to 32.4)22.7 (7.8 to 45.4)
Headache: Mild31.6 (12.6 to 56.6)12.5 (2.7 to 32.4)9.1 (1.1 to 29.2)
Headache: Moderate10.5 (1.3 to 33.1)0 (0.0 to 14.2)13.6 (2.9 to 34.9)
Headache: Severe0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Headache: Grade 40 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Chills: Any5.3 (0.1 to 26.0)0 (0.0 to 14.2)4.5 (0.1 to 22.8)
Chills: Mild0 (0.0 to 17.6)0 (0.0 to 14.2)4.5 (0.1 to 22.8)
Chills: Moderate5.3 (0.1 to 26.0)0 (0.0 to 14.2)0 (0.0 to 15.4)
Chills: Severe0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Chills: Grade 40 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Vomiting: Any5.3 (0.1 to 26.0)4.2 (0.1 to 21.1)0 (0.0 to 15.4)
Vomiting: Mild5.3 (0.1 to 26.0)0 (0.0 to 14.2)0 (0.0 to 15.4)
Vomiting: Moderate0 (0.0 to 17.6)4.2 (0.1 to 21.1)0 (0.0 to 15.4)
Vomiting: Severe0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Vomiting: Grade 40 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Diarrhea: Any10.5 (1.3 to 33.1)0 (0.0 to 14.2)4.5 (0.1 to 22.8)
Diarrhea: Mild10.5 (1.3 to 33.1)0 (0.0 to 14.2)4.5 (0.1 to 22.8)
Diarrhea: Moderate0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Diarrhea: Severe0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
Diarrhea: Grade 40 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
New or worsened muscle pain: Any5.3 (0.1 to 26.0)4.2 (0.1 to 21.1)0 (0.0 to 15.4)
New or worsened muscle pain: Mild0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
New or worsened muscle pain: Moderate5.3 (0.1 to 26.0)4.2 (0.1 to 21.1)0 (0.0 to 15.4)
New or worsened muscle pain: Severe0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
New or worsened muscle pain: Grade 40 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
New or worsened joint pain: Any10.5 (1.3 to 33.1)0 (0.0 to 14.2)0 (0.0 to 15.4)
New or worsened joint pain: Mild0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
New or worsened joint pain: Moderate10.5 (1.3 to 33.1)0 (0.0 to 14.2)0 (0.0 to 15.4)
New or worsened joint pain: Severe0 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
New or worsened joint pain: Grade 40 (0.0 to 17.6)0 (0.0 to 14.2)0 (0.0 to 15.4)
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=12 to <18 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Fever: Any14.3 ± 0.40 ± 0.00 ± 0.0
Fever: >=38.0 deg C to 38.4 deg C14.3 ± 0.40 ± 0.00 ± 0.0
Fever: >38.4 deg C to 38.9 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.9 deg C to 40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Any57.1 ± 18.40 ± 0.042.9 ± 9.9
Fatigue: Mild0 ± 0.00 ± 0.014.3 ± 0.4
Fatigue: Moderate57.1 ± 18.40 ± 0.028.6 ± 3.7
Fatigue: Severe0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Grade 40 ± 0.00 ± 0.00 ± 0.0
Headache: Any42.9 ± 9.90 ± 0.028.6 ± 3.7
Headache: Mild14.3 ± 0.40 ± 0.014.3 ± 0.4
Headache: Moderate28.6 ± 3.70 ± 0.014.3 ± 0.4
Headache: Severe0 ± 0.00 ± 0.00 ± 0.0
Headache: Grade 40 ± 0.00 ± 0.00 ± 0.0
Chills: Any14.3 ± 0.40 ± 0.00 ± 0.0
Chills: Mild14.3 ± 0.40 ± 0.00 ± 0.0
Chills: Moderate0 ± 0.00 ± 0.00 ± 0.0
Chills: Severe0 ± 0.00 ± 0.00 ± 0.0
Chills: Grade 40 ± 0.00 ± 0.00 ± 0.0
Vomiting: Any14.3 ± 0.40 ± 0.00 ± 0.0
Vomiting: Mild0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Moderate14.3 ± 0.40 ± 0.00 ± 0.0
Vomiting: Severe0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Grade 40 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Any14.3 ± 0.40 ± 0.028.6 ± 3.7
Diarrhea: Mild14.3 ± 0.40 ± 0.028.6 ± 3.7
Diarrhea: Moderate0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Severe0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Any42.9 ± 9.90 ± 0.042.9 ± 9.9
New or worsened muscle pain: Mild14.3 ± 0.40 ± 0.042.9 ± 9.9
New or worsened muscle pain: Moderate28.6 ± 3.70 ± 0.00 ± 0.0
New or worsened muscle pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Any14.3 ± 0.40 ± 0.00 ± 0.0
New or worsened joint pain: Mild14.3 ± 0.40 ± 0.00 ± 0.0
New or worsened joint pain: Moderate0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=18 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Fever: Any0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Fever: >=38.0 to 38.4 deg C0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Fever: >38.4 to 38.9 deg C0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Fever: >38.9 to 40.0 deg C0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Fever: >40.0 deg C0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Fatigue: Any60.0 (14.7 to 94.7)100.0 (2.5 to 100.0)100.0 (2.5 to 100.0)
Fatigue: Mild40.0 (5.3 to 85.3)100.0 (2.5 to 100.0)0 (0.0 to 97.5)
Fatigue: Moderate20.0 (0.5 to 71.6)0 (0.0 to 97.5)100.0 (2.5 to 100.0)
Fatigue: Severe0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Fatigue: Grade 40 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Headache: Any40.0 (5.3 to 85.3)0 (0.0 to 97.5)0 (0.0 to 97.5)
Headache: Mild20.0 (0.5 to 71.6)0 (0.0 to 97.5)0 (0.0 to 97.5)
Headache: Moderate20.0 (0.5 to 71.6)0 (0.0 to 97.5)0 (0.0 to 97.5)
Headache: Severe0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Headache: Grade 40 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Chills: Any0 (0.0 to 52.2)0 (0.0 to 97.5)100.0 (2.5 to 100.0)
Chills: Mild0 (0.0 to 52.2)0 (0.0 to 97.5)100.0 (2.5 to 100.0)
Chills: Moderate0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Chills: Severe0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Chills: Grade 40 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Vomiting: Any0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Vomiting: Mild0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Vomiting: Moderate0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Vomiting: Severe0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Vomiting: Grade 40 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Diarrhea: Any40.0 (5.3 to 85.3)100.0 (2.5 to 100.0)0 (0.0 to 97.5)
Diarrhea: Mild40.0 (5.3 to 85.3)0 (0.0 to 97.5)0 (0.0 to 97.5)
Diarrhea: Moderate0 (0.0 to 52.2)100.0 (2.5 to 100.0)0 (0.0 to 97.5)
Diarrhea: Severe0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
Diarrhea: Grade 40 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
New or worsened muscle pain: Any20.0 (0.5 to 71.6)100.0 (2.5 to 100.0)0 (0.0 to 97.5)
New or worsened muscle pain: Mild0 (0.0 to 52.2)100.0 (2.5 to 100.0)0 (0.0 to 97.5)
New or worsened muscle pain: Moderate20.0 (0.5 to 71.6)0 (0.0 to 97.5)0 (0.0 to 97.5)
New or worsened muscle pain: Severe0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
New or worsened muscle pain: Grade 40 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
New or worsened joint pain: Any20.0 (0.5 to 71.6)0 (0.0 to 97.5)0 (0.0 to 97.5)
New or worsened joint pain: Mild0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
New or worsened joint pain: Moderate20.0 (0.5 to 71.6)0 (0.0 to 97.5)0 (0.0 to 97.5)
New or worsened joint pain: Severe0 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
New or worsened joint pain: Grade 40 (0.0 to 52.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=2 to <5 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Fever: Any11.1 (0.3 to 48.2)0 (0.0 to 21.8)0 (0.0 to 30.8)
Fever: >=38.0 deg C to 38.4 deg C11.1 (0.3 to 48.2)0 (0.0 to 21.8)0 (0.0 to 30.8)
Fever: >38.4 deg C to 38.9 deg C0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Fever: >38.9 deg C to 40.0 deg C0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Fever: >40.0 deg C0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Fatigue: Any0 (0.0 to 33.6)6.7 (0.2 to 31.9)10.0 (0.3 to 44.5)
Fatigue: Mild0 (0.0 to 33.6)6.7 (0.2 to 31.9)10.0 (0.3 to 44.5)
Fatigue: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Fatigue: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Fatigue: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Headache: Any0 (0.0 to 33.6)6.7 (0.2 to 31.9)0 (0.0 to 30.8)
Headache: Mild0 (0.0 to 33.6)6.7 (0.2 to 31.9)0 (0.0 to 30.8)
Headache: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Headache: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Headache: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Chills: Any0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Chills: Mild0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Chills: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Chills: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Chills: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Vomiting: Any0 (0.0 to 33.6)13.3 (1.7 to 40.5)10.0 (0.3 to 44.5)
Vomiting: Mild0 (0.0 to 33.6)13.3 (1.7 to 40.5)0 (0.0 to 30.8)
Vomiting: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)10.0 (0.3 to 44.5)
Vomiting: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Vomiting: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Diarrhea: Any11.1 (0.3 to 48.2)6.7 (0.2 to 31.9)10.0 (0.3 to 44.5)
Diarrhea: Mild11.1 (0.3 to 48.2)6.7 (0.2 to 31.9)10.0 (0.3 to 44.5)
Diarrhea: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Diarrhea: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
Diarrhea: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened muscle pain: Any0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened muscle pain: Mild0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened muscle pain: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened muscle pain: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened muscle pain: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened joint pain: Any0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened joint pain: Mild0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened joint pain: Moderate0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened joint pain: Severe0 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
New or worsened joint pain: Grade 40 (0.0 to 33.6)0 (0.0 to 21.8)0 (0.0 to 30.8)
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=5 to <12 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Fever: Any5.3 ± 0.10 ± 0.04.5 ± 0.1
Fever: >=38.0 deg C to 38.4 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.4 deg C to 38.9 deg C5.3 ± 0.10 ± 0.04.5 ± 0.1
Fever: >38.9 deg C to 40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Any57.9 ± 33.537.5 ± 18.845.5 ± 24.4
Fatigue: Mild26.3 ± 9.120.8 ± 7.113.6 ± 2.9
Fatigue: Moderate31.6 ± 12.616.7 ± 4.731.8 ± 13.9
Fatigue: Severe0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Grade 40 ± 0.00 ± 0.00 ± 0.0
Headache: Any36.8 ± 16.329.2 ± 12.618.2 ± 5.2
Headache: Mild15.8 ± 3.412.5 ± 2.74.5 ± 0.1
Headache: Moderate21.1 ± 6.116.7 ± 4.713.6 ± 2.9
Headache: Severe0 ± 0.00 ± 0.00 ± 0.0
Headache: Grade 40 ± 0.00 ± 0.00 ± 0.0
Chills: Any21.1 ± 6.14.2 ± 0.14.5 ± 0.1
Chills: Mild10.5 ± 1.34.2 ± 0.10 ± 0.0
Chills: Moderate10.5 ± 1.30 ± 0.04.5 ± 0.1
Chills: Severe0 ± 0.00 ± 0.00 ± 0.0
Chills: Grade 40 ± 0.00 ± 0.00 ± 0.0
Vomiting: Any0 ± 0.012.5 ± 2.70 ± 0.0
Vomiting: Mild0 ± 0.012.5 ± 2.70 ± 0.0
Vomiting: Moderate0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Severe0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Grade 40 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Any5.3 ± 0.18.3 ± 1.04.5 ± 0.1
Diarrhea: Mild5.3 ± 0.14.2 ± 0.10 ± 0.0
Diarrhea: Moderate0 ± 0.04.2 ± 0.14.5 ± 0.1
Diarrhea: Severe0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Any10.5 ± 1.312.5 ± 2.74.5 ± 0.1
New or worsened muscle pain: Mild0 ± 0.04.2 ± 0.10 ± 0.0
New or worsened muscle pain: Moderate10.5 ± 1.38.3 ± 1.04.5 ± 0.1
New or worsened muscle pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Any15.8 ± 3.44.2 ± 0.14.5 ± 0.1
New or worsened joint pain: Mild0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Moderate15.8 ± 3.44.2 ± 0.14.5 ± 0.1
New or worsened joint pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=12 to <18 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Fever: Any28.6 ± 3.70 ± 0.00 ± 0.0
Fever: >=38.0 deg C to 38.4 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.4 deg C to 38.9 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.9 deg C to 40.0 deg C28.6 ± 3.70 ± 0.00 ± 0.0
Fever: >40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Any85.7 ± 42.10 ± 0.033.3 ± 4.3
Fatigue: Mild42.9 ± 9.90 ± 0.033.3 ± 4.3
Fatigue: Moderate28.6 ± 3.70 ± 0.00 ± 0.0
Fatigue: Severe14.3 ± 0.40 ± 0.00 ± 0.0
Fatigue: Grade 40 ± 0.00 ± 0.00 ± 0.0
Headache: Any71.4 ± 29.00 ± 0.016.7 ± 0.4
Headache: Mild28.6 ± 3.70 ± 0.016.7 ± 0.4
Headache: Moderate42.9 ± 9.90 ± 0.00 ± 0.0
Headache: Severe0 ± 0.00 ± 0.00 ± 0.0
Headache: Grade 40 ± 0.00 ± 0.00 ± 0.0
Chills: Any42.9 ± 9.90 ± 0.00 ± 0.0
Chills: Mild28.6 ± 3.70 ± 0.00 ± 0.0
Chills: Moderate14.3 ± 0.40 ± 0.00 ± 0.0
Chills: Severe0 ± 0.00 ± 0.00 ± 0.0
Chills: Grade 40 ± 0.00 ± 0.00 ± 0.0
Vomiting: Any28.6 ± 3.70 ± 0.00 ± 0.0
Vomiting: Mild14.3 ± 0.40 ± 0.00 ± 0.0
Vomiting: Moderate14.3 ± 0.40 ± 0.00 ± 0.0
Vomiting: Severe0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Grade 40 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Any14.3 ± 0.40 ± 0.00 ± 0.0
Diarrhea: Mild14.3 ± 0.40 ± 0.00 ± 0.0
Diarrhea: Moderate0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Severe0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Any42.9 ± 9.9100.0 ± 2.516.7 ± 0.4
New or worsened muscle pain: Mild0 ± 0.0100.0 ± 2.50 ± 0.0
New or worsened muscle pain: Moderate42.9 ± 9.90 ± 0.016.7 ± 0.4
New or worsened muscle pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Any28.6 ± 3.70 ± 0.00 ± 0.0
New or worsened joint pain: Mild28.6 ± 3.70 ± 0.00 ± 0.0
New or worsened joint pain: Moderate0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=18 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Fever: Any20.0 ± 0.50 ± 0.00 ± 0.0
Fever: >=38.0 to 38.4 deg C20.0 ± 0.50 ± 0.00 ± 0.0
Fever: >38.4 to 38.9 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.9 to 40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Any60.0 ± 14.7100.0 ± 2.50 ± 0.0
Fatigue: Mild0 ± 0.0100.0 ± 2.50 ± 0.0
Fatigue: Moderate60.0 ± 14.70 ± 0.00 ± 0.0
Fatigue: Severe0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Grade 40 ± 0.00 ± 0.00 ± 0.0
Headache: Any60.0 ± 14.7100.0 ± 2.50 ± 0.0
Headache: Mild20.0 ± 0.5100.0 ± 2.50 ± 0.0
Headache: Moderate40.0 ± 5.30 ± 0.00 ± 0.0
Headache: Severe0 ± 0.00 ± 0.00 ± 0.0
Headache: Grade 40 ± 0.00 ± 0.00 ± 0.0
Chills: Any40.0 ± 5.30 ± 0.00 ± 0.0
Chills: Mild0 ± 0.00 ± 0.00 ± 0.0
Chills: Moderate40.0 ± 5.30 ± 0.00 ± 0.0
Chills: Severe0 ± 0.00 ± 0.00 ± 0.0
Chills: Grade 40 ± 0.00 ± 0.00 ± 0.0
Vomiting: Any0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Mild0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Moderate0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Severe0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Grade 40 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Any60.0 ± 14.7100.0 ± 2.50 ± 0.0
Diarrhea: Mild40.0 ± 5.30 ± 0.00 ± 0.0
Diarrhea: Moderate20.0 ± 0.5100.0 ± 2.50 ± 0.0
Diarrhea: Severe0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Any20.0 ± 0.50 ± 0.00 ± 0.0
New or worsened muscle pain: Mild0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Moderate20.0 ± 0.50 ± 0.00 ± 0.0
New or worsened muscle pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Any20.0 ± 0.50 ± 0.00 ± 0.0
New or worsened joint pain: Mild0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Moderate20.0 ± 0.50 ± 0.00 ± 0.0
New or worsened joint pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=2 to <5 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Fever: Any0 ± 0.06.7 ± 0.20 ± 0.0
Fever: >=38.0 deg C to 38.4 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.4 deg C to 38.9 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.9 deg C to 40.0 deg C0 ± 0.06.7 ± 0.20 ± 0.0
Fever: >40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Any11.1 ± 0.36.7 ± 0.20 ± 0.0
Fatigue: Mild0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Moderate11.1 ± 0.36.7 ± 0.20 ± 0.0
Fatigue: Severe0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Grade 40 ± 0.00 ± 0.00 ± 0.0
Headache: Any0 ± 0.00 ± 0.00 ± 0.0
Headache: Mild0 ± 0.00 ± 0.00 ± 0.0
Headache: Moderate0 ± 0.00 ± 0.00 ± 0.0
Headache: Severe0 ± 0.00 ± 0.00 ± 0.0
Headache: Grade 40 ± 0.00 ± 0.00 ± 0.0
Chills: Any0 ± 0.00 ± 0.00 ± 0.0
Chills: Mild0 ± 0.00 ± 0.00 ± 0.0
Chills: Moderate0 ± 0.00 ± 0.00 ± 0.0
Chills: Severe0 ± 0.00 ± 0.00 ± 0.0
Chills: Grade 40 ± 0.00 ± 0.00 ± 0.0
Vomiting: Any0 ± 0.06.7 ± 0.20 ± 0.0
Vomiting: Mild0 ± 0.06.7 ± 0.20 ± 0.0
Vomiting: Moderate0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Severe0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Grade 40 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Any0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Mild0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Moderate0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Severe0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Any0 ± 0.06.7 ± 0.20 ± 0.0
New or worsened muscle pain: Mild0 ± 0.06.7 ± 0.20 ± 0.0
New or worsened muscle pain: Moderate0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Any0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Mild0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Moderate0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=5 to <12 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Fever: Any17.6 (3.8 to 43.4)0 (0.0 to 14.8)19.0 (5.4 to 41.9)
Fever: >=38.0 to 38.4 deg C11.8 (1.5 to 36.4)0 (0.0 to 14.8)14.3 (3.0 to 36.3)
Fever: >38.4 to 38.9 deg C0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Fever: >38.9 to 40.0 deg C0 (0.0 to 19.5)0 (0.0 to 14.8)4.8 (0.1 to 23.8)
Fever: >40.0 deg C0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Fever: Unknown5.9 (0.1 to 28.7)0 (0.0 to 14.8)0 (0.0 to 16.1)
Fatigue: Any47.1 (23.0 to 72.2)34.8 (16.4 to 57.3)52.4 (29.8 to 74.3)
Fatigue: Mild35.3 (14.2 to 61.7)13.0 (2.8 to 33.6)23.8 (8.2 to 47.2)
Fatigue: Moderate11.8 (1.5 to 36.4)21.7 (7.5 to 43.7)28.6 (11.3 to 52.2)
Fatigue: Severe0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Fatigue: Grade 40 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Headache: Any35.3 (14.2 to 61.7)8.7 (1.1 to 28.0)28.6 (11.3 to 52.2)
Headache: Mild29.4 (10.3 to 56.0)4.3 (0.1 to 21.9)9.5 (1.2 to 30.4)
Headache: Moderate5.9 (0.1 to 28.7)0 (0.0 to 14.8)19.0 (5.4 to 41.9)
Headache: Severe0 (0.0 to 19.5)4.3 (0.1 to 21.9)0 (0.0 to 16.1)
Headache: Grade 40 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Chills: Any17.6 (3.8 to 43.4)4.3 (0.1 to 21.9)14.3 (3.0 to 36.3)
Chills: Mild5.9 (0.1 to 28.7)4.3 (0.1 to 21.9)4.8 (0.1 to 23.8)
Chills: Moderate11.8 (1.5 to 36.4)0 (0.0 to 14.8)9.5 (3.0 to 36.3)
Chills: Severe0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Chills: Grade 40 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Vomiting: Any0 (0.0 to 19.5)0 (0.0 to 14.8)4.8 (0.1 to 23.8)
Vomiting: Mild0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Vomiting: Moderate0 (0.0 to 19.5)0 (0.0 to 14.8)4.8 (0.1 to 23.8)
Vomiting: Severe0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Vomiting: Grade 40 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Diarrhea: Any11.8 (1.5 to 36.4)0 (0.0 to 14.8)4.8 (0.1 to 23.8)
Diarrhea: Mild11.8 (1.5 to 36.4)0 (0.0 to 14.8)4.8 (0.1 to 23.8)
Diarrhea: Moderate0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Diarrhea: Severe0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
Diarrhea: Grade 40 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
New or worsened muscle pain: Any29.4 (10.3 to 56.0)13.0 (2.8 to 33.6)4.8 (0.1 to 23.8)
New or worsened muscle pain: Mild5.9 (0.1 to 28.7)13.0 (2.8 to 33.6)4.8 (0.1 to 23.8)
New or worsened muscle pain: Moderate23.5 (6.8 to 49.9)0 (0.0 to 14.8)0 (0.0 to 16.1)
New or worsened muscle pain: Severe0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
New or worsened muscle pain: Grade 40 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
New or worsened joint pain: Any11.8 (1.5 to 36.4)4.3 (2.8 to 33.6)4.8 (0.1 to 23.8)
New or worsened joint pain: Mild0 (0.0 to 19.5)4.3 (2.8 to 33.6)4.8 (0.1 to 23.8)
New or worsened joint pain: Moderate11.8 (1.5 to 36.4)0 (0.0 to 14.8)0 (0.0 to 16.1)
New or worsened joint pain: Severe0 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
New or worsened joint pain: Grade 40 (0.0 to 19.5)0 (0.0 to 14.8)0 (0.0 to 16.1)
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=12 to <18 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Fever: Any42.9 (9.9 to 81.6)0 (0.0 to 97.5)33.3 (4.3 to 77.7)
Fever: >=38.0 to 38.4 deg C28.6 (3.7 to 71.0)0 (0.0 to 97.5)33.3 (4.3 to 77.7)
Fever: >38.4°C to 38.9 deg C14.3 (0.4 to 57.9)0 (0.0 to 97.5)0 (0.0 to 45.9)
Fever: >38.9°C to 40.0 deg C0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Fever: >40.0 deg C0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Fatigue: Any85.7 (42.1 to 99.6)100.0 (2.5 to 100.0)50.0 (11.8 to 88.2)
Fatigue: Mild14.3 (0.4 to 57.9)100.0 (2.5 to 100.0)50.0 (11.8 to 88.2)
Fatigue: Moderate71.4 (29.0 to 96.3)0 (0.0 to 97.5)0 (0.0 to 45.9)
Fatigue: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Fatigue: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Headache: Any85.7 (42.1 to 99.6)100.0 (2.5 to 100.0)66.7 (22.3 to 95.7)
Headache: Mild28.6 (3.7 to 71.0)100.0 (2.5 to 100.0)33.3 (4.3 to 77.7)
Headache: Moderate57.1 (18.4 to 90.1)0 (0.0 to 97.5)33.3 (4.3 to 77.7)
Headache: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Headache: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Chills: Any71.4 (29.0 to 96.3)100.0 (2.5 to 100.0)16.7 (0.4 to 64.1)
Chills: Mild14.3 (0.4 to 57.9)100.0 (2.5 to 100.0)16.7 (0.4 to 64.1)
Chills: Moderate57.1 (18.4 to 90.1)0 (0.0 to 97.5)0 (0.0 to 45.9)
Chills: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Chills: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Vomiting: Any0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Vomiting: Mild0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Vomiting: Moderate0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Vomiting: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Vomiting: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Diarrhea: Any14.3 (0.4 to 57.9)0 (0.0 to 97.5)33.3 (4.3 to 77.7)
Diarrhea: Mild14.3 (0.4 to 57.9)0 (0.0 to 97.5)33.3 (4.3 to 77.7)
Diarrhea: Moderate0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Diarrhea: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
Diarrhea: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
New or worsened muscle pain: Any28.6 (3.7 to 71.0)0 (0.0 to 97.5)16.7 (0.4 to 64.1)
New or worsened muscle pain: Mild14.3 (0.4 to 57.9)0 (0.0 to 97.5)16.7 (0.4 to 64.1)
New or worsened muscle pain: Moderate14.3 (0.4 to 57.9)0 (0.0 to 97.5)0 (0.0 to 45.9)
New or worsened muscle pain: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
New or worsened muscle pain: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
New or worsened joint pain: Any14.3 (0.4 to 57.9)0 (0.0 to 97.5)0 (0.0 to 45.9)
New or worsened joint pain: Mild0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
New or worsened joint pain: Moderate14.3 (0.4 to 57.9)0 (0.0 to 97.5)0 (0.0 to 45.9)
New or worsened joint pain: Severe0 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
New or worsened joint pain: Grade 40 (0.0 to 41.0)0 (0.0 to 97.5)0 (0.0 to 45.9)
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=18 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Fever:Any0 (0.0 to 60.2)—0 (0.0 to 97.5)
Fever: >=38.0 to 38.4 deg C0 (0.0 to 60.2)—0 (0.0 to 97.5)
Fever: >38.4 to 38.9 deg C0 (0.0 to 60.2)—0 (0.0 to 97.5)
Fever: >38.9 to 40.0 deg C0 (0.0 to 60.2)—0 (0.0 to 97.5)
Fever: >40.0 deg C0 (0.0 to 60.2)—0 (0.0 to 97.5)
Fatigue: Any75.0 (19.4 to 99.4)—0 (0.0 to 97.5)
Fatigue: Mild50.0 (6.8 to 93.2)—0 (0.0 to 97.5)
Fatigue: Moderate25.0 (0.6 to 80.6)—0 (0.0 to 97.5)
Fatigue: Severe0 (0.0 to 60.2)—0 (0.0 to 97.5)
Fatigue: Grade 40 (0.0 to 60.2)—0 (0.0 to 97.5)
Headache: Any75.0 (19.4 to 99.4)—0 (0.0 to 97.5)
Headache: Mild25.0 (0.6 to 80.6)—0 (0.0 to 97.5)
Headache: Moderate50.0 (6.8 to 93.2)—0 (0.0 to 97.5)
Headache: Severe0 (0.0 to 60.2)—0 (0.0 to 97.5)
Headache: Grade 40 (0.0 to 60.2)—0 (0.0 to 97.5)
Chills: Any50.0 (6.8 to 93.2)—0 (0.0 to 97.5)
Chills: Mild25.0 (0.6 to 80.6)—0 (0.0 to 97.5)
Chills: Moderate25.0 (0.6 to 80.6)—0 (0.0 to 97.5)
Chills: Severe0 (0.0 to 60.2)—0 (0.0 to 97.5)
Chills: Grade 40 (0.0 to 60.2)—0 (0.0 to 97.5)
Vomiting: Any0 (0.0 to 60.2)—0 (0.0 to 97.5)
Vomiting: Mild0 (0.0 to 60.2)—0 (0.0 to 97.5)
Vomiting: Moderate0 (0.0 to 60.2)—0 (0.0 to 97.5)
Vomiting: Severe0 (0.0 to 60.2)—0 (0.0 to 97.5)
Vomiting: Grade 40 (0.0 to 60.2)—0 (0.0 to 97.5)
Diarrhea: Any25.0 (0.6 to 80.6)—0 (0.0 to 97.5)
Diarrhea: Mild0 (0.0 to 60.2)—0 (0.0 to 97.5)
Diarrhea: Moderate25.0 (0.6 to 80.6)—0 (0.0 to 97.5)
Diarrhea: Severe0 (0.0 to 60.2)—0 (0.0 to 97.5)
Diarrhea: Grade 40 (0.0 to 60.2)—0 (0.0 to 97.5)
New or worsened muscle pain: Any50.0 (6.8 to 93.2)—0 (0.0 to 97.5)
New or worsened muscle pain: Mild0 (0.0 to 60.2)—0 (0.0 to 97.5)
New or worsened muscle pain: Moderate50.0 (6.8 to 93.2)—0 (0.0 to 97.5)
New or worsened muscle pain: Severe0 (0.0 to 60.2)—0 (0.0 to 97.5)
New or worsened muscle pain: Grade 40 (0.0 to 60.2)—0 (0.0 to 97.5)
New or worsened joint pain: Any50.0 (6.8 to 93.2)—0 (0.0 to 97.5)
New or worsened joint pain: Mild0 (0.0 to 60.2)—0 (0.0 to 97.5)
New or worsened joint pain: Moderate50.0 (6.8 to 93.2)—0 (0.0 to 97.5)
New or worsened joint pain: Severe0 (0.0 to 60.2)—0 (0.0 to 97.5)
New or worsened joint pain: Grade 40 (0.0 to 60.2)—0 (0.0 to 97.5)
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=2 to <5 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Fever: Any28.6 ± 3.70 ± 0.00 ± 0.0
Fever: >=38.0 to 38.4 deg C14.3 ± 0.40 ± 0.00 ± 0.0
Fever: >38.4 to 38.9 deg C14.3 ± 0.40 ± 0.00 ± 0.0
Fever: >38.9 to 40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Any14.3 ± 0.40 ± 0.016.7 ± 0.4
Fatigue: Mild14.3 ± 0.40 ± 0.016.7 ± 0.4
Fatigue: Moderate0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Severe0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Grade 40 ± 0.00 ± 0.00 ± 0.0
Headache: Any0 ± 0.00 ± 0.00 ± 0.0
Headache: Mild0 ± 0.00 ± 0.00 ± 0.0
Headache: Moderate0 ± 0.00 ± 0.00 ± 0.0
Headache: Severe0 ± 0.00 ± 0.00 ± 0.0
Headache: Grade 40 ± 0.00 ± 0.00 ± 0.0
Chills: Any14.3 ± 0.416.7 ± 0.40 ± 0.0
Chills: Mild0 ± 0.016.7 ± 0.40 ± 0.0
Chills: Moderate14.3 ± 0.40 ± 0.00 ± 0.0
Chills: Severe0 ± 0.00 ± 0.00 ± 0.0
Chills: Grade 40 ± 0.00 ± 0.00 ± 0.0
Vomiting: Any0 ± 0.016.7 ± 0.40 ± 0.0
Vomiting: Mild0 ± 0.016.7 ± 0.40 ± 0.0
Vomiting: Moderate0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Severe0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Grade 40 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Any14.3 ± 0.40 ± 0.00 ± 0.0
Diarrhea: Mild14.3 ± 0.40 ± 0.00 ± 0.0
Diarrhea: Moderate0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Severe0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Any0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Mild0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Moderate0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Any0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Mild0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Moderate0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=5 to <12 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 de, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Fever: Any8.3 ± 0.25.3 ± 0.16.7 ± 0.2
Fever: >=38.0 to 38.4 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.4 to 38.9 deg C0 ± 0.00 ± 0.00 ± 0.0
Fever: >38.9 to 40.0 deg C8.3 ± 0.25.3 ± 0.16.7 ± 0.2
Fever: >40.0 deg C0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Any50.0 ± 21.126.3 ± 9.133.3 ± 11.8
Fatigue: Mild33.3 ± 9.910.5 ± 1.313.3 ± 1.7
Fatigue: Moderate16.7 ± 2.115.8 ± 3.420.0 ± 4.3
Fatigue: Severe0 ± 0.00 ± 0.00 ± 0.0
Fatigue: Grade 40 ± 0.00 ± 0.00 ± 0.0
Headache: Any33.3 ± 9.921.1 ± 6.113.3 ± 1.7
Headache: Mild8.3 ± 0.215.8 ± 3.40 ± 0.0
Headache: Moderate25.0 ± 5.55.3 ± 0.16.7 ± 0.2
Headache: Severe0 ± 0.00 ± 0.06.7 ± 0.2
Headache: Grade 40 ± 0.00 ± 0.00 ± 0.0
Chills: Any8.3 ± 0.25.3 ± 0.113.3 ± 1.7
Chills: Mild8.3 ± 0.25.3 ± 0.10 ± 0.0
Chills: Moderate0 ± 0.00 ± 0.013.3 ± 1.7
Chills: Severe0 ± 0.00 ± 0.00 ± 0.0
Chills: Grade 40 ± 0.00 ± 0.00 ± 0.0
Vomiting: Any8.3 ± 0.25.3 ± 0.10 ± 0.0
Vomiting: Mild8.3 ± 0.25.3 ± 0.10 ± 0.0
Vomiting: Moderate0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Severe0 ± 0.00 ± 0.00 ± 0.0
Vomiting: Grade 40 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Any25.0 ± 5.515.8 ± 3.46.7 ± 0.2
Diarrhea: Mild25.0 ± 5.510.5 ± 1.36.7 ± 0.2
Diarrhea: Moderate0 ± 0.05.3 ± 0.10 ± 0.0
Diarrhea: Severe0 ± 0.00 ± 0.00 ± 0.0
Diarrhea: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened muscle pain: Any16.7 ± 2.115.8 ± 3.46.7 ± 0.2
New or worsened muscle pain: Mild0 ± 0.015.8 ± 3.40 ± 0.0
New or worsened muscle pain: Moderate8.3 ± 0.20 ± 0.06.7 ± 0.2
New or worsened muscle pain: Severe8.3 ± 0.20 ± 0.00 ± 0.0
New or worsened muscle pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Any25.0 ± 5.50 ± 0.06.7 ± 0.2
New or worsened joint pain: Mild8.3 ± 0.20 ± 0.06.7 ± 0.2
New or worsened joint pain: Moderate16.7 ± 2.10 ± 0.00 ± 0.0
New or worsened joint pain: Severe0 ± 0.00 ± 0.00 ± 0.0
New or worsened joint pain: Grade 40 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=12 to <18 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Fever: Any25.0 (0.6 to 80.6)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Fever: >=38.0 to 38.4 deg C0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Fever: >38.4 to 38.9 deg C25.0 (0.6 to 80.6)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Fever: >38.9 to 40.0 deg C0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Fever: >40.0 deg C0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Fatigue: Any50.0 (6.8 to 93.2)100.0 (2.5 to 100.0)66.7 (9.4 to 99.2)
Fatigue: Mild0 (0.0 to 60.2)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Fatigue: Moderate50.0 (6.8 to 93.2)100.0 (2.5 to 100.0)33.3 (0.8 to 90.6)
Fatigue: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Fatigue: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Headache: Any25.0 (0.6 to 80.6)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Headache: Mild0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Headache: Moderate25.0 (0.6 to 80.6)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Headache: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Headache: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Chills: Any25.0 (0.6 to 80.6)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Chills: Mild25.0 (0.6 to 80.6)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Chills: Moderate0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Chills: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Chills: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Vomiting: Any0 (0.0 to 60.2)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Vomiting: Mild0 (0.0 to 60.2)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Vomiting: Moderate0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Vomiting: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Vomiting: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Diarrhea: Any0 (0.0 to 60.2)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Diarrhea: Mild0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Diarrhea: Moderate0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
Diarrhea: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
Diarrhea: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
New or worsened muscle pain: Any25.0 (0.6 to 80.6)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
New or worsened muscle pain: Mild0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
New or worsened muscle pain: Moderate25.0 (0.6 to 80.6)0 (0.0 to 97.5)33.3 (0.8 to 90.6)
New or worsened muscle pain: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
New or worsened muscle pain: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 97.5)
New or worsened joint pain: Any0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
New or worsened joint pain: Mild0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
New or worsened joint pain: Moderate0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
New or worsened joint pain: Severe0 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
New or worsened joint pain: Grade 40 (0.0 to 60.2)0 (0.0 to 97.5)0 (0.0 to 70.8)
PrimaryPercentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=18 Years

Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Fever: Any0 ± 0.00 ± 0.0—
Fever: >=38.0 to 38.4 deg C0 ± 0.00 ± 0.0—
Fever: >38.4 to 38.9 deg C0 ± 0.00 ± 0.0—
Fever: >38.9 to 40.0 deg C0 ± 0.00 ± 0.0—
Fever: >40.0 deg C0 ± 0.00 ± 0.0—
Fatigue: Any66.7 ± 9.40 ± 0.0—
Fatigue: Mild33.3 ± 0.80 ± 0.0—
Fatigue: Moderate33.3 ± 0.80 ± 0.0—
Fatigue: Severe0 ± 0.00 ± 0.0—
Fatigue: Grade 40 ± 0.00 ± 0.0—
Headache: Any33.3 ± 0.80 ± 0.0—
Headache: Mild33.3 ± 0.80 ± 0.0—
Headache: Moderate0 ± 0.00 ± 0.0—
Headache: Severe0 ± 0.00 ± 0.0—
Headache: Grade 40 ± 0.00 ± 0.0—
Chills: Any33.3 ± 0.80 ± 0.0—
Chills: Mild0 ± 0.00 ± 0.0—
Chills: Moderate33.3 ± 0.80 ± 0.0—
Chills: Severe0 ± 0.00 ± 0.0—
Chills: Grade 40 ± 0.00 ± 0.0—
Vomiting: Any0 ± 0.00 ± 0.0—
Vomiting: Mild0 ± 0.00 ± 0.0—
Vomiting: Moderate0 ± 0.00 ± 0.0—
Vomiting: Severe0 ± 0.00 ± 0.0—
Vomiting: Grade 40 ± 0.00 ± 0.0—
Diarrhea: Any0 ± 0.00 ± 0.0—
Diarrhea: Mild0 ± 0.00 ± 0.0—
Diarrhea: Moderate0 ± 0.00 ± 0.0—
Diarrhea: Severe0 ± 0.00 ± 0.0—
Diarrhea: Grade 40 ± 0.00 ± 0.0—
New or worsened muscle pain: Any33.3 ± 0.80 ± 0.0—
New or worsened muscle pain: Mild0 ± 0.00 ± 0.0—
New or worsened muscle pain: Moderate33.3 ± 0.80 ± 0.0—
New or worsened muscle pain: Severe0 ± 0.00 ± 0.0—
New or worsened muscle pain: Grade 40 ± 0.00 ± 0.0—
New or worsened joint pain: Any33.3 ± 0.80 ± 0.0—
New or worsened joint pain: Mild0 ± 0.00 ± 0.0—
New or worsened joint pain: Moderate33.3 ± 0.80 ± 0.0—
New or worsened joint pain: Severe0 ± 0.00 ± 0.0—
New or worsened joint pain: Grade 40 ± 0.00 ± 0.0—
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event (AE) After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=2 to <5 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 1 to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event (AE) After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Percentage of Participants Reporting at Least 1 Adverse Event (AE) After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=2 to <5 Years44.4 ± 13.733.3 ± 11.838.5 ± 13.9
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=5 to <12 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 1 to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=5 to <12 Years36.8 (16.3 to 61.6)8.3 (1.0 to 27.0)27.3 (10.7 to 50.2)
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=12 to <18 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 1 to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=12 to <18 Years14.3 ± 0.40 ± 0.014.3 ± 0.4
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=18 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 1 to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=18 Years20.0 ± 0.50 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 3 to 1 month after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years33.3 ± 7.540.0 ± 16.30 ± 0.0
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 3 to 1 month after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years29.4 ± 10.38.7 ± 1.14.5 ± 0.1
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=12 to <18 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 3 to 1 month after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=12 to <18 Years14.3 ± 0.40 ± 0.016.7 ± 0.4
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event After Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=18 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 3 to 1 month after Vaccination 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=18 Years0 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 4 to 1 month after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years14.3 ± 0.416.7 ± 0.40 ± 0.0
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 4 to 1 month after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years0 ± 0.036.8 ± 16.30 ± 0.0
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=12 to <18 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 4 to 1 month after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=12 to <18 Years0 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting at Least 1 Adverse Event After Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=18 Years

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 4 to 1 month after Vaccination 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=18 Years0 ± 0.0100.0 ± 2.5—
PrimaryPercentage of Participants Reporting Serious Adverse Events (SAEs) From Vaccination 1 Through the Duration of the Study in Participants Aged >=2 to <5 Years

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events (SAEs) From Vaccination 1 Through the Duration of the Study in Participants Aged >=2 to <5 Years
Percentage of participants>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant
Percentage of Participants Reporting Serious Adverse Events (SAEs) From Vaccination 1 Through the Duration of the Study in Participants Aged >=2 to <5 Years0 ± 0.053.3 ± 26.623.1 ± 5.0
PrimaryPercentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=5 to <12 Years

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=5 to <12 Years
Percentage of participants>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant
Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=5 to <12 Years15.8 ± 3.420.8 ± 7.113.6 ± 2.9
PrimaryPercentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=12 to <18 Years

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=12 to <18 Years
Percentage of participants>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant
Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=12 to <18 Years0 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants Reporting SAEs From Dose 1 Through the Duration of the Study in Participants Aged >=18 Years

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting SAEs From Dose 1 Through the Duration of the Study in Participants Aged >=18 Years
Percentage of participants>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Percentage of Participants Reporting SAEs From Dose 1 Through the Duration of the Study in Participants Aged >=18 Years20.0 ± 0.50 ± 0.0100.0 ± 2.5

Adverse events

Collected over Local reactions/systemic events (systematic assessment): Day 1 to Day 7 after each dose. Non-systematic assessment: AEs were reported from Day 1 of dose 1 up to 1 month after dose 4 (approximately 9 months). For SAE, from Dose 1 on Day 1 to 6 months after Dose 4 (approximately 14 months).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
>=2 to <5 Years With Immunomodulatory Therapy0/9 (0%)0/9 (0%)8/9 (88.9%)
>=2 to <5 Years With Solid Organ Transplant0/15 (0%)8/15 (53.3%)13/15 (86.7%)
>=2 to <5 Years With Stem Cell Transplant0/13 (0%)3/13 (23.1%)10/13 (76.9%)
>=5 to <12 Years With Immunomodulatory Therapy0/19 (0%)3/19 (15.8%)18/19 (94.7%)
>=5 to <12 Years With Solid Organ Transplant0/24 (0%)5/24 (20.8%)23/24 (95.8%)
>=5 to <12 Years With Stem Cell Transplant0/22 (0%)3/22 (13.6%)22/22 (100%)
>=12 to <18 Years With Immunomodulatory Therapy0/7 (0%)0/7 (0%)7/7 (100%)
>=12 to <18 Years With Solid Organ Transplant0/1 (0%)0/1 (0%)1/1 (100%)
>=12 to <18 Years With Stem Cell Transplant0/7 (0%)0/7 (0%)6/7 (85.7%)
>=18 Years With Immunomodulatory Therapy0/5 (0%)1/5 (20%)4/5 (80%)
>=18 Years With Non-Small Cell Lung Cancer0/1 (0%)0/1 (0%)1/1 (100%)
>= 18 Years With Haemodialysis0/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
Event>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
MelaenaGastrointestinal disorders0/90/150/130/190/240/220/70/10/70/50/11/1
AzotaemiaRenal and urinary disorders0/90/150/130/190/240/220/70/10/70/50/11/1
GangreneInfections and infestations0/90/150/130/190/240/220/70/10/70/50/11/1
Renal colicRenal and urinary disorders0/90/150/130/190/240/220/70/10/71/50/10/1
GastroenteritisInfections and infestations0/92/150/130/191/240/220/70/10/70/50/10/1
Urinary tract infectionInfections and infestations0/92/150/131/190/240/220/70/10/70/50/10/1
Dental cariesGastrointestinal disorders0/90/151/130/190/240/220/70/10/70/50/10/1
BronchiolitisInfections and infestations0/90/151/130/190/240/220/70/10/70/50/10/1
PyrexiaGeneral disorders0/90/151/130/190/240/220/70/10/70/50/10/1
Pulmonary vein stenosisRespiratory, thoracic and mediastinal disorders0/91/150/130/190/240/220/70/10/70/50/10/1
Most frequent other events
Showing 10 of 88
Most frequent other events
Event>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With Haemodialysis
Headache (HEADACHE)Nervous system disorders0/91/150/1311/1911/249/227/71/16/74/51/10/1
Diarrhoea (DIARRHEA)Gastrointestinal disorders2/93/152/135/195/242/222/70/12/73/51/10/1
Myalgia (NEW OR WORSENED MUSCLE PAIN)Musculoskeletal and connective tissue disorders1/91/150/136/198/243/223/71/13/72/51/10/1
Urinary tract infectionInfections and infestations0/93/150/130/193/240/221/71/10/71/50/10/1
Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/90/150/130/190/240/220/70/10/70/51/10/1
Chills (CHILLS)General disorders2/91/151/137/193/245/225/71/11/72/50/11/1
Fatigue (FATIGUE)General disorders3/93/153/1314/1917/2414/226/71/15/74/51/11/1
Injection site pain (PAIN AT INJECTION SITE)General disorders4/93/154/1316/1918/2419/226/71/15/74/51/11/1
Swelling (SWELLING)General disorders1/91/151/135/194/248/222/71/12/71/50/10/1
Vomiting (VOMITING)Gastrointestinal disorders1/93/154/132/194/241/223/70/11/70/50/10/1

Baseline characteristics

Safety population included all participants who received at least 1 dose of study intervention. To avoid risk of identification of participant, any baseline measure data is not disclosed for reporting arm including (\>=18 Years with Non-Small Cell Lung Cancer, \>= 18 Years with Haemodialysis) and baseline measure data other than age is not disclosed for reporting arm (\>=12 to \<18 Years with Solid Organ Transplant) and reported the participant under category- Not Disclosed

Age, Customized
Age, Customized(Participants)>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With HaemodialysisTotal
Children (2-11 years)91513192422000000102
Adolescents (12-17 years)00000071700015
Adults (18-64 years)0000000003003
From 65-84 years0000000002002
Not disclosed0000000000112
Sex/Gender, Customized
Sex/Gender, Customized(Participants)>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With HaemodialysisTotal
Female483129520530051
Male57107151750220070
Not disclosed0000000100113
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With HaemodialysisTotal
Hispanic or Latino11462230120022
Not Hispanic or Latino814913221940630098
Unknown or Not Reported0000010000001
Not Disclosed0000000100113
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)>=2 to <5 Years With Immunomodulatory Therapy>=2 to <5 Years With Solid Organ Transplant>=2 to <5 Years With Stem Cell Transplant>=5 to <12 Years With Immunomodulatory Therapy>=5 to <12 Years With Solid Organ Transplant>=5 to <12 Years With Stem Cell Transplant>=12 to <18 Years With Immunomodulatory Therapy>=12 to <18 Years With Solid Organ Transplant>=12 to <18 Years With Stem Cell Transplant>=18 Years With Immunomodulatory Therapy>=18 Years With Non-Small Cell Lung Cancer>= 18 Years With HaemodialysisTotal
Asian0100101000003
Black or African American0201030002008
White91112172119607100103
More than one race0010100001003
Unknown or Not Reported0101100001004
Not disclosed0000000100113
08

Study locations

30 sites
  • Ochsner Clinic Foundation
    Jefferson, Louisiana 70121, United States
  • Ochsner Medical Center - Jefferson Highway
    Jefferson, Louisiana 70121, United States
  • Ochsner Clinic Foundation
    Kenner, Louisiana 70065, United States
  • Ochsner Medical Center Kenner
    Kenner, Louisiana 70065, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Ochsner Medical Center - Jefferson Highway
    New Orleans, Louisiana 70121, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Henry Ford Hospital - Research Pharmacy
    Detroit, Michigan 48202, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45206, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Cincinnati Children's Hospital Vaccine Research Center
    Cincinnati, Ohio 45229, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Research Institute: Building Cure
    Seattle, Washington 98101, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, RIO Grande DO SUL 90035-903, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, RIO Grande DO SUL 90410000, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    Sao Jose do Rio Preto, SAO Paulo 15090-000, Brazil
  • GRAACC - Grupo de Apoio ao Adolescente e à Criança com Câncer
    São Paulo, 04039-001, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
  • Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)
    Berlin, 13353, Germany
  • Charité - Universitaetsmedizin
    Berlin, 13353, Germany
  • Charité Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • IKF Pneumologie GmbH & Co KG
    Frankfurt am Main, 60596, Germany
  • Studiengesellschaft BSF UG.
    Halle (Saale), 06108, Germany
  • Studiengesellschaft BSF Unternehmergesellschaft
    Halle (Saale), 06108, Germany
  • Studiengesellschaft BSF Unternehmergesellschaft
    Halle(Saale), 06108, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20359, Germany
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez" de la Universidad Autonoma de Nuevo Leon
    Monterrey, N.l. 64460, Mexico
  • Centro Médico Zambrano Hellion
    San Pedro Garza Garcia, Nuevo LEÓN 66278, Mexico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2023, 21 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 21 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2021
First posted
May 21, 2021
StartActual
Oct 15, 2021
Primary completionActual
Jul 23, 2023
CompletionActual
Jul 23, 2023
Results first posted
Oct 9, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04895982
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
May 21, 2021
Start date
Oct 15, 2021
Primary completion
Jul 23, 2023
Completion
Jul 23, 2023
Results posted
Oct 9, 2024
Last update
Oct 9, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion